Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT
Trial design: A randomised, parallel-group, double-blind, placebo-controlled multicentre study with health economic and nested qualitative studies to determine if mifepristone (Mifegyne®, Exelgyn, Paris, France) plus misoprostol is superior to misoprostol alone for the resolution of missed miscarria...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
NIHR Journals Library
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a7b7fdf1ce9c4e479354a4c24a6277e0 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a7b7fdf1ce9c4e479354a4c24a6277e0 |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
pregnancy mifepristone misoprostol missed miscarriage medical management gestational sac randomised controlled trial Medical technology R855-855.5 |
| spellingShingle |
pregnancy mifepristone misoprostol missed miscarriage medical management gestational sac randomised controlled trial Medical technology R855-855.5 Adam Devall Justin Chu Leanne Beeson Pollyanna Hardy Versha Cheed Yongzhong Sun Tracy Roberts Chidubem Okeke Ogwulu Eleanor Williams Laura Jones Jenny La Fontaine Papadopoulos Ruth Bender-Atik Jane Brewin Kim Hinshaw Meenakshi Choudhary Amna Ahmed Joel Naftalin Natalie Nunes Abigail Oliver Feras Izzat Kalsang Bhatia Ismail Hassan Yadava Jeve Judith Hamilton Shilpa Deb Cecilia Bottomley Jackie Ross Linda Watkins Martyn Underwood Ying Cheong Chitra Kumar Pratima Gupta Rachel Small Stewart Pringle Frances Hodge Anupama Shahid Ioannis Gallos Andrew Horne Siobhan Quenby Arri Coomarasamy Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT |
| description |
Trial design: A randomised, parallel-group, double-blind, placebo-controlled multicentre study with health economic and nested qualitative studies to determine if mifepristone (Mifegyne®, Exelgyn, Paris, France) plus misoprostol is superior to misoprostol alone for the resolution of missed miscarriage. Methods: Women diagnosed with missed miscarriage in the first 14 weeks of pregnancy were randomly assigned (1 : 1 ratio) to receive 200 mg of oral mifepristone or matched placebo, followed by 800 μg of misoprostol 2 days later. A web-based randomisation system allocated the women to the two groups, with minimisation for age, body mass index, parity, gestational age, amount of bleeding and randomising centre. The primary outcome was failure to pass the gestational sac within 7 days after randomisation. The prespecified key secondary outcome was requirement for surgery to resolve the miscarriage. A within-trial cost-effectiveness study and a nested qualitative study were also conducted. Women who completed the trial protocol were purposively approached to take part in an interview to explore their satisfaction with and the acceptability of medical management of missed miscarriage. Results: A total of 711 women, from 28 hospitals in the UK, were randomised to receive either mifepristone plus misoprostol (357 women) or placebo plus misoprostol (354 women). The follow-up rate for the primary outcome was 98% (696 out of 711 women). The risk of failure to pass the gestational sac within 7 days was 17% (59 out of 348 women) in the mifepristone plus misoprostol group, compared with 24% (82 out of 348 women) in the placebo plus misoprostol group (risk ratio 0.73, 95% confidence interval 0.54 to 0.98; p = 0.04). Surgical intervention to resolve the miscarriage was needed in 17% (62 out of 355 women) in the mifepristone plus misoprostol group, compared with 25% (87 out of 353 women) in the placebo plus misoprostol group (risk ratio 0.70, 95% confidence interval 0.52 to 0.94; p = 0.02). There was no evidence of a difference in the incidence of adverse events between the two groups. A total of 42 women, 19 in the mifepristone plus misoprostol group and 23 in the placebo plus misoprostol group, took part in an interview. Women appeared to have a preference for active management of their miscarriage. Overall, when women experienced care that supported their psychological well-being throughout the care pathway, and information was delivered in a skilled and sensitive manner such that women felt informed and in control, they were more likely to express satisfaction with medical management. The use of mifepristone and misoprostol showed an absolute effect difference of 6.6% (95% confidence interval 0.7% to 12.5%). The average cost per woman was lower in the mifepristone plus misoprostol group, with a cost saving of £182 (95% confidence interval £26 to £338). Therefore, the use of mifepristone and misoprostol for the medical management of a missed miscarriage dominated the use of misoprostol alone. Limitations: The results from this trial are not generalisable to women diagnosed with incomplete miscarriage and the study does not allow for a comparison with expectant or surgical management of miscarriage. Future work: Future work should use existing data to assess and rank the relative clinical effectiveness and safety profiles for all methods of management of miscarriage. Conclusions: Our trial showed that pre-treatment with mifepristone followed by misoprostol resulted in a higher rate of resolution of missed miscarriage than misoprostol treatment alone. Women were largely satisfied with medical management of missed miscarriage and would choose it again. The mifepristone and misoprostol intervention was shown to be cost-effective in comparison to misoprostol alone. Trial registration: Current Controlled Trials ISRCTN17405024. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 68. See the NIHR Journals Library website for further project information. |
| format |
article |
| author |
Adam Devall Justin Chu Leanne Beeson Pollyanna Hardy Versha Cheed Yongzhong Sun Tracy Roberts Chidubem Okeke Ogwulu Eleanor Williams Laura Jones Jenny La Fontaine Papadopoulos Ruth Bender-Atik Jane Brewin Kim Hinshaw Meenakshi Choudhary Amna Ahmed Joel Naftalin Natalie Nunes Abigail Oliver Feras Izzat Kalsang Bhatia Ismail Hassan Yadava Jeve Judith Hamilton Shilpa Deb Cecilia Bottomley Jackie Ross Linda Watkins Martyn Underwood Ying Cheong Chitra Kumar Pratima Gupta Rachel Small Stewart Pringle Frances Hodge Anupama Shahid Ioannis Gallos Andrew Horne Siobhan Quenby Arri Coomarasamy |
| author_facet |
Adam Devall Justin Chu Leanne Beeson Pollyanna Hardy Versha Cheed Yongzhong Sun Tracy Roberts Chidubem Okeke Ogwulu Eleanor Williams Laura Jones Jenny La Fontaine Papadopoulos Ruth Bender-Atik Jane Brewin Kim Hinshaw Meenakshi Choudhary Amna Ahmed Joel Naftalin Natalie Nunes Abigail Oliver Feras Izzat Kalsang Bhatia Ismail Hassan Yadava Jeve Judith Hamilton Shilpa Deb Cecilia Bottomley Jackie Ross Linda Watkins Martyn Underwood Ying Cheong Chitra Kumar Pratima Gupta Rachel Small Stewart Pringle Frances Hodge Anupama Shahid Ioannis Gallos Andrew Horne Siobhan Quenby Arri Coomarasamy |
| author_sort |
Adam Devall |
| title |
Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT |
| title_short |
Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT |
| title_full |
Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT |
| title_fullStr |
Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT |
| title_full_unstemmed |
Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT |
| title_sort |
mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the mifemiso rct |
| publisher |
NIHR Journals Library |
| publishDate |
2021 |
| url |
https://doaj.org/article/a7b7fdf1ce9c4e479354a4c24a6277e0 |
| work_keys_str_mv |
AT adamdevall mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT justinchu mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT leannebeeson mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT pollyannahardy mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT vershacheed mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT yongzhongsun mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT tracyroberts mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT chidubemokekeogwulu mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT eleanorwilliams mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT laurajones mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT jennylafontainepapadopoulos mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT ruthbenderatik mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT janebrewin mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT kimhinshaw mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT meenakshichoudhary mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT amnaahmed mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT joelnaftalin mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT natalienunes mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT abigailoliver mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT ferasizzat mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT kalsangbhatia mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT ismailhassan mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT yadavajeve mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT judithhamilton mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT shilpadeb mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT ceciliabottomley mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT jackieross mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT lindawatkins mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT martynunderwood mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT yingcheong mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT chitrakumar mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT pratimagupta mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT rachelsmall mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT stewartpringle mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT franceshodge mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT anupamashahid mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT ioannisgallos mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT andrewhorne mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT siobhanquenby mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct AT arricoomarasamy mifepristoneandmisoprostolversusplaceboandmisoprostolforresolutionofmiscarriageinwomendiagnosedwithmissedmiscarriagethemifemisorct |
| _version_ |
1718413274881458176 |
| spelling |
oai:doaj.org-article:a7b7fdf1ce9c4e479354a4c24a6277e02021-11-25T16:16:35ZMifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT1366-52782046-492410.3310/hta25680https://doaj.org/article/a7b7fdf1ce9c4e479354a4c24a6277e02021-11-01T00:00:00Zhttps://doi.org/10.3310/hta25680https://doaj.org/toc/1366-5278https://doaj.org/toc/2046-4924Trial design: A randomised, parallel-group, double-blind, placebo-controlled multicentre study with health economic and nested qualitative studies to determine if mifepristone (Mifegyne®, Exelgyn, Paris, France) plus misoprostol is superior to misoprostol alone for the resolution of missed miscarriage. Methods: Women diagnosed with missed miscarriage in the first 14 weeks of pregnancy were randomly assigned (1 : 1 ratio) to receive 200 mg of oral mifepristone or matched placebo, followed by 800 μg of misoprostol 2 days later. A web-based randomisation system allocated the women to the two groups, with minimisation for age, body mass index, parity, gestational age, amount of bleeding and randomising centre. The primary outcome was failure to pass the gestational sac within 7 days after randomisation. The prespecified key secondary outcome was requirement for surgery to resolve the miscarriage. A within-trial cost-effectiveness study and a nested qualitative study were also conducted. Women who completed the trial protocol were purposively approached to take part in an interview to explore their satisfaction with and the acceptability of medical management of missed miscarriage. Results: A total of 711 women, from 28 hospitals in the UK, were randomised to receive either mifepristone plus misoprostol (357 women) or placebo plus misoprostol (354 women). The follow-up rate for the primary outcome was 98% (696 out of 711 women). The risk of failure to pass the gestational sac within 7 days was 17% (59 out of 348 women) in the mifepristone plus misoprostol group, compared with 24% (82 out of 348 women) in the placebo plus misoprostol group (risk ratio 0.73, 95% confidence interval 0.54 to 0.98; p = 0.04). Surgical intervention to resolve the miscarriage was needed in 17% (62 out of 355 women) in the mifepristone plus misoprostol group, compared with 25% (87 out of 353 women) in the placebo plus misoprostol group (risk ratio 0.70, 95% confidence interval 0.52 to 0.94; p = 0.02). There was no evidence of a difference in the incidence of adverse events between the two groups. A total of 42 women, 19 in the mifepristone plus misoprostol group and 23 in the placebo plus misoprostol group, took part in an interview. Women appeared to have a preference for active management of their miscarriage. Overall, when women experienced care that supported their psychological well-being throughout the care pathway, and information was delivered in a skilled and sensitive manner such that women felt informed and in control, they were more likely to express satisfaction with medical management. The use of mifepristone and misoprostol showed an absolute effect difference of 6.6% (95% confidence interval 0.7% to 12.5%). The average cost per woman was lower in the mifepristone plus misoprostol group, with a cost saving of £182 (95% confidence interval £26 to £338). Therefore, the use of mifepristone and misoprostol for the medical management of a missed miscarriage dominated the use of misoprostol alone. Limitations: The results from this trial are not generalisable to women diagnosed with incomplete miscarriage and the study does not allow for a comparison with expectant or surgical management of miscarriage. Future work: Future work should use existing data to assess and rank the relative clinical effectiveness and safety profiles for all methods of management of miscarriage. Conclusions: Our trial showed that pre-treatment with mifepristone followed by misoprostol resulted in a higher rate of resolution of missed miscarriage than misoprostol treatment alone. Women were largely satisfied with medical management of missed miscarriage and would choose it again. The mifepristone and misoprostol intervention was shown to be cost-effective in comparison to misoprostol alone. Trial registration: Current Controlled Trials ISRCTN17405024. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 68. See the NIHR Journals Library website for further project information.Adam DevallJustin ChuLeanne BeesonPollyanna HardyVersha CheedYongzhong SunTracy RobertsChidubem Okeke OgwuluEleanor WilliamsLaura JonesJenny La Fontaine PapadopoulosRuth Bender-AtikJane BrewinKim HinshawMeenakshi ChoudharyAmna AhmedJoel NaftalinNatalie NunesAbigail OliverFeras IzzatKalsang BhatiaIsmail HassanYadava JeveJudith HamiltonShilpa DebCecilia BottomleyJackie RossLinda WatkinsMartyn UnderwoodYing CheongChitra KumarPratima GuptaRachel SmallStewart PringleFrances HodgeAnupama ShahidIoannis GallosAndrew HorneSiobhan QuenbyArri CoomarasamyNIHR Journals Libraryarticlepregnancymifepristonemisoprostolmissed miscarriagemedical managementgestational sacrandomised controlled trialMedical technologyR855-855.5ENHealth Technology Assessment, Vol 25, Iss 68 (2021) |